Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806712 | 0.89 | BDKRB1 (0.38) | CNR2STAT6BDKRB1MAPK9MAPK10 | |
| SCHEMBL2809623 | 0.89 | BDKRB1 (0.39) | BDKRB1MAPK9MAPK10AURKASCD | |
| SCHEMBL185038 | 0.87 | AURKA (0.33) | CNR2STAT6BDKRB1MAPK9MAPK10 | |
| SCHEMBL2807536 | 0.84 | MYC (0.39) | BDKRB1AURKASCDPTK2 | |
| SCHEMBL2807539 | 0.84 | MYC (0.39) | BDKRB1AURKASCDPTK2 | |
| SCHEMBL185703 | 0.84 | FAAH (0.37) | CNR2BDKRB1MAPK9MAPK10AURKA | |
| SCHEMBL2804848 | 0.83 | BDKRB1 (0.38) | BDKRB1MAPK9MAPK10AURKASCD | |
| SCHEMBL2812065 | 0.83 | HDAC3 (0.38) | BDKRB1MAPK9MAPK10AURKASCD | |
| SCHEMBL2806528 | 0.83 | HPGD (0.41) | CNR2BDKRB1P2RX7 | |
| SCHEMBL2807542 | 0.82 | NAMPT (0.39) | BDKRB1MAPK9MAPK10AURKASCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CNR2 882/4885STAT6 2279/4885BDKRB1 289/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | CNR2 882/4885STAT6 2279/4885BDKRB1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.